Corrigendum to “Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022” [Obes Pillars 2 (2022) 100018] (S2667368122000092), (10.1016/j.obpill.2022.100018)

Harold E. Bays; Angela Fitch; Sandra Christensen; Karli Burridge; Justin Tondt

doi:10.1016/j.obpill.2022.100035

Corrigendum to “Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022” [Obes Pillars 2 (2022) 100018] (S2667368122000092), (10.1016/j.obpill.2022.100018)

Harold E. Bays, Angela Fitch, Sandra Christensen, Karli Burridge, Justin Tondt

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

The authors wish to report a word/drug name error on page 16: In Section 5.11.6, it states: “T-cell lymphoma has been reported in patients with acquired generalized lipodystrophy, both treated and not treated with setmelanotide.” This should read: “T-cell lymphoma has been reported in patients with acquired generalized lipodystrophy, both treated and not treated with metreleptin”. The authors apologise for the error.

Original language	English (US)
Article number	100035
Journal	Obesity Pillars
Volume	4
DOIs	https://doi.org/10.1016/j.obpill.2022.100035
State	Published - Dec 2022

All Science Journal Classification (ASJC) codes

Endocrinology, Diabetes and Metabolism
Dentistry (miscellaneous)
Nutrition and Dietetics
Endocrinology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.obpill.2022.100035

Cite this

Bays, H. E., Fitch, A., Christensen, S., Burridge, K., & Tondt, J. (2022). Corrigendum to “Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022” [Obes Pillars 2 (2022) 100018] (S2667368122000092), (10.1016/j.obpill.2022.100018). Obesity Pillars, 4, Article 100035. https://doi.org/10.1016/j.obpill.2022.100035

@article{749acbe4688442dfabc2d671591928be,

title = "Corrigendum to “Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022” [Obes Pillars 2 (2022) 100018] (S2667368122000092), (10.1016/j.obpill.2022.100018)",

abstract = "The authors wish to report a word/drug name error on page 16: In Section 5.11.6, it states: “T-cell lymphoma has been reported in patients with acquired generalized lipodystrophy, both treated and not treated with setmelanotide.” This should read: “T-cell lymphoma has been reported in patients with acquired generalized lipodystrophy, both treated and not treated with metreleptin”. The authors apologise for the error.",

author = "Bays, {Harold E.} and Angela Fitch and Sandra Christensen and Karli Burridge and Justin Tondt",

note = "Publisher Copyright: {\textcopyright} 2022 The Author(s)",

year = "2022",

month = dec,

doi = "10.1016/j.obpill.2022.100035",

language = "English (US)",

volume = "4",

journal = "Obesity Pillars",

issn = "2667-3681",

}

Bays, HE, Fitch, A, Christensen, S, Burridge, K & Tondt, J 2022, 'Corrigendum to “Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022” [Obes Pillars 2 (2022) 100018] (S2667368122000092), (10.1016/j.obpill.2022.100018)', Obesity Pillars, vol. 4, 100035. https://doi.org/10.1016/j.obpill.2022.100035

Corrigendum to “Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022” [Obes Pillars 2 (2022) 100018] (S2667368122000092), (10.1016/j.obpill.2022.100018). / Bays, Harold E.; Fitch, Angela; Christensen, Sandra et al.
In: Obesity Pillars, Vol. 4, 100035, 12.2022.

Research output: Contribution to journal › Comment/debate › peer-review

TY - JOUR

T1 - Corrigendum to “Anti-Obesity Medications and Investigational Agents

T2 - An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022” [Obes Pillars 2 (2022) 100018] (S2667368122000092), (10.1016/j.obpill.2022.100018)

AU - Bays, Harold E.

AU - Fitch, Angela

AU - Christensen, Sandra

AU - Burridge, Karli

AU - Tondt, Justin

PY - 2022/12

Y1 - 2022/12

N2 - The authors wish to report a word/drug name error on page 16: In Section 5.11.6, it states: “T-cell lymphoma has been reported in patients with acquired generalized lipodystrophy, both treated and not treated with setmelanotide.” This should read: “T-cell lymphoma has been reported in patients with acquired generalized lipodystrophy, both treated and not treated with metreleptin”. The authors apologise for the error.

AB - The authors wish to report a word/drug name error on page 16: In Section 5.11.6, it states: “T-cell lymphoma has been reported in patients with acquired generalized lipodystrophy, both treated and not treated with setmelanotide.” This should read: “T-cell lymphoma has been reported in patients with acquired generalized lipodystrophy, both treated and not treated with metreleptin”. The authors apologise for the error.

UR - http://www.scopus.com/inward/record.url?scp=85192482571&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85192482571&partnerID=8YFLogxK

U2 - 10.1016/j.obpill.2022.100035

DO - 10.1016/j.obpill.2022.100035

M3 - Comment/debate

AN - SCOPUS:85192482571

SN - 2667-3681

VL - 4

JO - Obesity Pillars

JF - Obesity Pillars

M1 - 100035

ER -

Corrigendum to “Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022” [Obes Pillars 2 (2022) 100018] (S2667368122000092), (10.1016/j.obpill.2022.100018)

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Cite this